What the Evidence Says About Psychedelic-Assisted Therapy for Addiction in 2026
Ibogaine, psilocybin, MDMA, ketamine — the clinical trial landscape is broader than the headlines suggest, but so are the caveats.
Body: [Balanced evidence review: psilocybin for AUD (Johns Hopkins, NYU), ibogaine for OUD (Stanford, Kentucky’s state-funded research), MDMA (field setback after 2024 FDA rejection, what changed), ketamine (already approved for depression, off-label for AUD), what the meta-analyses actually show, safety concerns, regulatory pathway. Concludes with: “promising but not yet ready for routine care.” 900 words.]
Sources Cited
- 01.Ahttps://heal.nih.govNIH HEAL
- 02.Ahttps://clinicaltrials.govClinicalTrials.gov
Filed Under
Peer-Reviewed ResearchMAT — BuprenorphineFederal
Continue reading
More from this section
RFK Jr. Put Psychedelics on a Federal Fast Lane. Here's Who Stands to Benefit.
A Trump executive order on April 18 fast-tracks psychedelic therapies through FDA review, and the FDA awarded National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics. Compass is targeting a rolling NDA submission in Q4 2026.
Science & MedicineThree Days Away: The FDA Is About to Rule on the First New Quit-Smoking Drug in 20 Years
The FDA's PDUFA deadline for cytisinicline is June 20, 2026 — three days away. If approved, it would be the first new FDA-approved smoking cessation drug since varenicline in 2006, and the foundation for a coming vaping cessation program.
Science & MedicineThe Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.